US Drug Recall Register
Class II · Moderate risk Terminated Initiated Dec 14, 2018 (8 years ago)

Nevirapine Extended Release Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specifications.

What was recalled

Nevirapine Extended Release Tablets, 400 mg, 30-count bottle, Rx Only, Manufactured by: Cipla Ltd. Verna Goa, India, Manufactured for: Cipla USA Inc. 9100 S Dadeland Blvd., Suite 1500 Miami, FL 33156, NDC 69097-403-02

Recalling firm
Cipla Limited
NDC code
69097-403-02
Origin
India
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0382-2019

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Pine recalls

See all
Class II · Moderate risk Ongoing

Amlodipine and Olmesartan Medoxomil Tablets

Reason Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications

Ascend Laboratories, LLC D-0712-2026
Class II · Moderate risk Ongoing

Cleviprex

Reason Lack of Assurance of Sterility

Chiesi USA, Inc. NDC 10122-611-10 D-0689-2026
Class III · Low risk Ongoing

Epinephrine Injection

Reason Failed Impurities/Degradations Specifications

Fresenius Kabi USA, LLC NDC 63323-696-02 D-0581-2026
Class II · Moderate risk Ongoing

Amlodipine and Olmesartan Medoxomil Tablets

Reason Failed Dissolution Specifications: Olmesartan Medoxomil content below specifications

Ascend Laboratories, LLC NDC 67877-501-30 D-0556-2026
Class II · Moderate risk Ongoing

EPINEPHRINE Injection

Reason Lack of Assurance of Sterility

International Medication Systems Ltd. NDC 76329-3318-1 D-0483-2026